Should I buy or sell Sonnet BioTherapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SONN shares. View SONN analyst ratings or view top-rated stocks .

What is Sonnet BioTherapeutics' stock price target for 2024?

2 analysts have issued twelve-month target prices for Sonnet BioTherapeutics' shares. Their SONN share price targets range from $30.00 to $30.00. On average, they expect the company's share price to reach $30.00 in the next year. This suggests a possible upside of 1,564.3% from the stock's current price. View analysts price targets for SONN or view top-rated stocks among Wall Street analysts .

How have SONN shares performed in 2024?

Sonnet BioTherapeutics' stock was trading at $1.74 on January 1st, 2024. Since then, SONN shares have increased by 3.6% and is now trading at $1.8026. View the best growth stocks for 2024 here .

Are investors shorting Sonnet BioTherapeutics?

Sonnet BioTherapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 452,200 shares, a decrease of 18.9% from the March 15th total of 557,500 shares. Based on an average daily volume of 101,000 shares, the days-to-cover ratio is currently 4.5 days. Approximately 16.3% of the company's shares are short sold. View Sonnet BioTherapeutics' Short Interest .

When is Sonnet BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SONN earnings forecast .

How were Sonnet BioTherapeutics' earnings last quarter?

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million for the quarter. Sonnet BioTherapeutics had a negative trailing twelve-month return on equity of 519.54% and a negative net margin of 11,187.19%.

When did Sonnet BioTherapeutics' stock split?

Sonnet BioTherapeutics's stock reverse split before market open on Friday, September 1st 2023. The 1-22 reverse split was announced on Friday, September 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Sonnet BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO) , Sorrento Therapeutics (SRNE) , Boxlight (BOXL) , T2 Biosystems (TTOO) , Biocept (BIOC) , iBio (IBIO) , Trevena (TRVN) , Vaxart (VXRT) , ADMA Biologics (ADMA) and Advanced Micro Devices (AMD) .

How do I buy shares of Sonnet BioTherapeutics?

Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SONN

Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free SONN Stock Alerts

$1.82

+0.05 (+2.82%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.77
▼
$1.89
50-Day Range: $1.51
▼
$2.26
52-Week Range: $1.08
▼
$26.40

Volume: 22,114 shs
Average Volume: 91,645 shs
Market Capitalization: $5.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Get Sonnet BioTherapeutics alerts:

Sonnet BioTherapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,564.3% Upside
$30.00 Price Target
Short Interest: Healthy
16.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.10 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Sonnet BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Sonnet BioTherapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
16.27% of the float of Sonnet BioTherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sonnet BioTherapeutics has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Sonnet BioTherapeutics has recently decreased by 18.89%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sonnet BioTherapeutics does not currently pay a dividend.
Dividend Growth
Sonnet BioTherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SONN.

1.8

News and Social Media Coverage

News Sentiment
Sonnet BioTherapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Sonnet BioTherapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Sonnet BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sonnet BioTherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Sonnet BioTherapeutics is held by insiders.
Percentage Held by Institutions
Only 9.45% of the stock of Sonnet BioTherapeutics is held by institutions.

0.0

Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Sonnet BioTherapeutics Stock (NASDAQ:SONN)

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

SONN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SONN Stock News Headlines

April 17, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)

April 15, 2024 | americanbankingnews.com

Short Interest in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Declines By 18.9%

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)

March 11, 2024 | finance.yahoo.com

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective

March 1, 2024 | morningstar.com

Sonnet BioTherapeutics Holdings Inc Ordinary Shares SONN

February 29, 2024 | finanznachrichten.de

Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

February 29, 2024 | msn.com

Sonnet BioTherapeutics Reported SON-1010 Phase I Trial Results: Demonstrates Safety, Efficacy in Melanoma Model, and Potential for Dose Escalation

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 17, 2024 | finance.yahoo.com

Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations

February 14, 2024 | finance.yahoo.com

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

February 7, 2024 | msn.com

Nasdaq panel expected to decide on Yield10 listing within next month

January 1, 2024 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

December 22, 2023 | msn.com

Sonnet BioTherapeutics files for $100M mixed shelf

December 21, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

December 16, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Sonnet BioTherapeutics Amid Promising Oncology Trials and Financial Fortitude

December 14, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

October 31, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

October 26, 2023 | benzinga.com

What's Happening With Sonnet BioTherapeutics (SONN) Shares?

October 25, 2023 | markets.businessinsider.com

Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results

October 25, 2023 | msn.com

Sonnet BioTherapeutics down 32%, prices $4.55M stock offering

October 25, 2023 | benzinga.com

Why Sonnet BioTherapeutics (SONN) Stock Is Getting Hammered

October 25, 2023 | marketwatch.com

Sonnet BioTherapeutics Shares Slide Premarket After Stock Offering

October 25, 2023 | msn.com

Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?

October 25, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

October 17, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

October 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Aldeyra Therapeutics (ALDX)

See More Headlines

Receive SONN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SONN
CUSIP: N/A
CIK: 1106838
Web: www.chanticleerholdings.com
Phone: 609-375-2227
Fax: 704-366-2463
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.00
High Stock Price Target: $30.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +1,548.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,830,000.00
Net Margins: -11,187.19%
Pretax Margin: -11,187.19%
Return on Equity: -519.54%
Return on Assets: -169.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.74
Quick Ratio: 1.74

Sales & Book Value

Annual Sales: $150,000.00
Price / Sales: 37.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.13) per share
Price / Book: -14.00

Miscellaneous

Outstanding Shares: 3,070,000
Free Float: 3,008,000
Market Cap: $5.59 million
Optionable: Not Optionable
Beta: 0.64

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Pankaj Mohan Ph.D. (Age 59)
Founder, Chairman, CEO & President
Comp: $927k
Dr. John K. Cini Ph.D. (Age 71)
Chief Scientific Officer & Co-Founder
Comp: $602.48k
Mr. Jay Cross (Age 54)
Chief Financial Officer
Comp: $603.42k
Mr. Donald J. Griffith CPA (Age 75)
CPA, Controller & Director
Comp: $134.05k
Ms. Susan Dexter (Age 69)
Chief Technical Officer
Dr. Richard T. Kenney FACP (Age 66)
M.D., Chief Medical Officer
Mr. Manuel Dafonseca
Head of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SONN Stock Analysis - Frequently Asked Questions

Should I buy or sell Sonnet BioTherapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SONN shares.
View SONN analyst ratings or view top-rated stocks.
What is Sonnet BioTherapeutics' stock price target for 2024?: 2 analysts have issued twelve-month target prices for Sonnet BioTherapeutics' shares. Their SONN share price targets range from $30.00 to $30.00. On average, they expect the company's share price to reach $30.00 in the next year. This suggests a possible upside of 1,564.3% from the stock's current price.
View analysts price targets for SONN or view top-rated stocks among Wall Street analysts.
How have SONN shares performed in 2024?: Sonnet BioTherapeutics' stock was trading at $1.74 on January 1st, 2024. Since then, SONN shares have increased by 3.6% and is now trading at $1.8026.
View the best growth stocks for 2024 here.
Are investors shorting Sonnet BioTherapeutics?: Sonnet BioTherapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 452,200 shares, a decrease of 18.9% from the March 15th total of 557,500 shares. Based on an average daily volume of 101,000 shares, the days-to-cover ratio is currently 4.5 days. Approximately 16.3% of the company's shares are short sold.
View Sonnet BioTherapeutics' Short Interest.
When is Sonnet BioTherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SONN earnings forecast.

How were Sonnet BioTherapeutics' earnings last quarter?: Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million for the quarter. Sonnet BioTherapeutics had a negative trailing twelve-month return on equity of 519.54% and a negative net margin of 11,187.19%.
When did Sonnet BioTherapeutics' stock split?: Sonnet BioTherapeutics's stock reverse split before market open on Friday, September 1st 2023. The 1-22 reverse split was announced on Friday, September 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Sonnet BioTherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO), Sorrento Therapeutics (SRNE), Boxlight (BOXL), T2 Biosystems (TTOO), Biocept (BIOC), iBio (IBIO), Trevena (TRVN), Vaxart (VXRT), ADMA Biologics (ADMA) and Advanced Micro Devices (AMD).
How do I buy shares of Sonnet BioTherapeutics?: Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SONN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis

Sonnet BioTherapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth